Treatment of Early Stage Renal Failure With Active Vitamin D or a Phosphate Binder.
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
Patients with reduced renal function normally develop hyperparathyroidism, which in turn is
associated with increased cardiovascular risk and de-calcification. Hyperparathyroidism may
be enhanced by an increased level of FGF23 which is often seen in the early stage of renal
failure. This pilot study will investigate the FGF23-lowering effect of early initiation of
treatment with a phosphate binder versus active vitamin D in an open crossover design.
Phase:
Phase 2
Details
Lead Sponsor:
Helse Stavanger HF
Collaborator:
Rikshospitalet University Hospital
Treatments:
Alfacalcidol Hydroxycholecalciferols Sevelamer Vitamin D